Novel Modifiers of Toll-like and RIG-like Receptor Signaling

Toll 样和 RIG 样受体信号传导的新型修饰剂

基本信息

项目摘要

DESCRIPTION (provided by applicant): Innate immunity of an organism is the in born protection against invading pathogens. Innate immune receptors sense components of invading organisms and trigger immune and inflammatory responses to combat infectious agents. In this proposal we intend to target three human innate immune receptors which among others are involved in detecting virus infection. We will use high throughput screening to identify chemical and small interfering RNA modifiers, which will specifically modulate Toll-like Receptor 3, Retinoic acid Inducible gene I and Toll-like receptor 7 signaling pathways. During the course of this investigation, we would like to find efficient modifiers, test their specificity, and make them available to the research community. We have successfully developed and used high throughput screening experiments to target one of the innate immune receptor - Toll-like Receptor 3. Using a cell-based readout system to screen for inhibitors we have identified novel signaling pathways involved in TLR3 mediated IRF3 activation and cytokine induction. In this proposal we will collaborate with University of Pittsburgh Drug Discovery Institute (DDI) to take advantage of the high throughput screening and drug development expertise of DDI to expand our screening efforts. This project will not only generate novel reagents for studying innate immune receptor signaling pathways, but may also provide building blocks for future drug development, which can be used to treat inflammatory diseases caused by virus infection. RELEVANCE: Innate immune receptors are the first line of sensors to recognize various components of invading pathogens and trigger immune and inflammatory responses to combat the infectious agent. We propose to target a few of these receptors which are involved in sensing virus infections, and identify novel reagents capable of modulating the functions of these receptors. Our long-term goal is to use these specific reagents to treat inflammatory and auto-immune diseases, which are caused by over or under-action of these receptors.
描述(由申请人提供):生物体的先天免疫是针对入侵病原体的天生保护。先天免疫受体感知入侵生物体的成分并触发免疫和炎症反应以对抗传染源。在这项提案中,我们打算针对三种人类先天免疫受体,其中包括参与检测病毒感染的受体。我们将使用高通量筛选来鉴定化学和小干扰 RNA 修饰剂,这些修饰剂将特异性调节 Toll 样受体 3、视黄酸诱导基因 I 和 Toll 样受体 7 信号通路。在这项调查过程中,我们希望找到有效的修饰剂,测试它们的特异性,并将它们提供给研究界。 我们已经成功开发并使用高通量筛选实验来靶向先天免疫受体之一 - Toll 样受体 3。使用基于细胞的读出系统来筛选抑制剂,我们已经确定了参与 TLR3 介导的 IRF3 激活和细胞因子诱导的新信号传导途径。在本提案中,我们将与匹兹堡大学药物发现研究所 (DDI) 合作,利用 DDI 的高通量筛选和药物开发专业知识来扩大我们的筛选工作。该项目不仅将产生用于研究先天免疫受体信号通路的新型试剂,还可能为未来药物开发提供基础材料,用于治疗由病毒感染引起的炎症性疾病。 相关性:先天免疫受体是识别入侵病原体的各种成分并触发免疫和炎症反应以对抗传染源的第一线传感器。我们建议针对其中一些参与感知病毒感染的受体,并鉴定能够调节这些受体功能的新型试剂。我们的长期目标是使用这些特定试剂来治疗由这些受体过度或不足引起的炎症和自身免疫性疾病。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Saumendra N Sarkar其他文献

Hitching RIG to action
将索具系到动作上
  • DOI:
    10.1038/ni1105-1074
  • 发表时间:
    2005-11-01
  • 期刊:
  • 影响因子:
    27.600
  • 作者:
    Ganes C Sen;Saumendra N Sarkar
  • 通讯作者:
    Saumendra N Sarkar

Saumendra N Sarkar的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Saumendra N Sarkar', 18)}}的其他基金

Differential modulation of RIG-I and cGAS signaling by OASL and its role in antiviral response
OASL 对 RIG-I 和 cGAS 信号传导的差异调节及其在抗病毒反应中的作用
  • 批准号:
    9263213
  • 财政年份:
    2016
  • 资助金额:
    $ 28.5万
  • 项目类别:
Differential modulation of RIG-I and cGAS signaling by OASL and its role in antiviral response.
OASL 对 RIG-I 和 cGAS 信号传导的差异调节及其在抗病毒反应中的作用。
  • 批准号:
    9240591
  • 财政年份:
    2015
  • 资助金额:
    $ 28.5万
  • 项目类别:
Differential modulation of RIG-I and cGAS signaling by OASL and its role in antiviral response.
OASL 对 RIG-I 和 cGAS 信号传导的差异调节及其在抗病毒反应中的作用。
  • 批准号:
    9054802
  • 财政年份:
    2015
  • 资助金额:
    $ 28.5万
  • 项目类别:
Creation of Immuno-Oncolytic Viruses for Cancer Therapy
创造用于癌症治疗的免疫溶瘤病毒
  • 批准号:
    9246445
  • 财政年份:
    2014
  • 资助金额:
    $ 28.5万
  • 项目类别:
Novel Modifiers of Toll-like and RIG-like Receptor Signaling
Toll 样和 RIG 样受体信号传导的新型修饰剂
  • 批准号:
    8032514
  • 财政年份:
    2009
  • 资助金额:
    $ 28.5万
  • 项目类别:
Novel Modifiers of Toll-like and RIG-like Receptor Signaling
Toll 样和 RIG 样受体信号传导的新型修饰剂
  • 批准号:
    7664688
  • 财政年份:
    2009
  • 资助金额:
    $ 28.5万
  • 项目类别:
Novel Modifiers of Toll-like and RIG-like Receptor Signaling
Toll 样和 RIG 样受体信号传导的新型修饰剂
  • 批准号:
    7779404
  • 财政年份:
    2009
  • 资助金额:
    $ 28.5万
  • 项目类别:
Novel Modifiers of Toll-like and RIG-like Receptor Signaling
Toll 样和 RIG 样受体信号传导的新型修饰剂
  • 批准号:
    8431811
  • 财政年份:
    2009
  • 资助金额:
    $ 28.5万
  • 项目类别:

相似海外基金

Defining new asthma phenotypes using high-dimensional data
使用高维数据定义新的哮喘表型
  • 批准号:
    2901112
  • 财政年份:
    2024
  • 资助金额:
    $ 28.5万
  • 项目类别:
    Studentship
Basophilic oncostatin M fuels nociceptor neuron-induced asthma
嗜碱性制瘤素 M 促进伤害感受器神经元诱发哮喘
  • 批准号:
    485504
  • 财政年份:
    2023
  • 资助金额:
    $ 28.5万
  • 项目类别:
    Salary Programs
Engaging Patient and Caregivers in Using Patient-reported Outcomes Measures in Pediatric Clinical Care for Asthma
让患者和护理人员参与儿科哮喘儿科临床护理中患者报告的结果测量
  • 批准号:
    495593
  • 财政年份:
    2023
  • 资助金额:
    $ 28.5万
  • 项目类别:
Air pollution and Asthma in Canada: Projections of burden and the value of climate adaptation strategies
加拿大的空气污染和哮喘:负担预测和气候适应战略的价值
  • 批准号:
    485322
  • 财政年份:
    2023
  • 资助金额:
    $ 28.5万
  • 项目类别:
    Operating Grants
Data-driven model links BMIz to gene expression in pediatric asthma
数据驱动模型将 BMIz 与小儿哮喘基因表达联系起来
  • 批准号:
    493135
  • 财政年份:
    2023
  • 资助金额:
    $ 28.5万
  • 项目类别:
BIOlogic drug safety and effectiveness interNational pharmacoepidemiologIC study in pregnant women with autoimmune disorders and asthma and their children (BIONIC)
患有自身免疫性疾病和哮喘的孕妇及其子女的生物药物安全性和有效性国际药物流行病学研究(BIONIC)
  • 批准号:
    493526
  • 财政年份:
    2023
  • 资助金额:
    $ 28.5万
  • 项目类别:
    Operating Grants
A Novel Approach to Target Neutrophilic Airway Inflammation and Airway Hyperresponsiveness in Therapy-Resistant (Refractory) Asthma.
一种针对难治性哮喘中性粒细胞性气道炎症和气道高反应性的新方法。
  • 批准号:
    10659658
  • 财政年份:
    2023
  • 资助金额:
    $ 28.5万
  • 项目类别:
Treating Maternal Depression in an Urban Community-Based Pediatric Asthma Clinic: Targeting Maternal Mood, Child Asthma Outcomes, and Health Disparities
在城市社区小儿哮喘诊所治疗孕产妇抑郁症:针对孕产妇情绪、儿童哮喘结果和健康差异
  • 批准号:
    10723233
  • 财政年份:
    2023
  • 资助金额:
    $ 28.5万
  • 项目类别:
Improving Prediction of Asthma-related Outcomes with Genetic Ancestry-informed Lung Function Equations
利用遗传祖先信息的肺功能方程改善哮喘相关结果的预测
  • 批准号:
    10723861
  • 财政年份:
    2023
  • 资助金额:
    $ 28.5万
  • 项目类别:
Prenatal Fatty Acid Supplementation and Early Childhood Asthma and Atopy in Black American Families
美国黑人家庭产前脂肪酸补充剂与儿童早期哮喘和特应性
  • 批准号:
    10586398
  • 财政年份:
    2023
  • 资助金额:
    $ 28.5万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了